A group of Russian companies belonging to the Skolkovo Foundation and Cuba’s Heber Biotec S.A company signed four memorandums of understanding intended to strengthen strategic cooperation in biomedicine.
R-Pharm and Chemrar companies, the Stem Cell Institute and the Center of Oncology signed the agreements with Heber Biotec S.A, which has the patent right for the commercialization of the products and projects developed by the Biotechnology and Genetic Engineering Center (CIGB) and other leading suppliers of the Cuban pharmaceutical market.
It means a lot to have signed these memorandums of understanding with four leading Russian partners, not to mention Skolkovo’s support for the CIGB, said the president of Heber Biotec S.A, Eulogio Pimentel.
Referring to the signing of the documents in Havana, Pimentel noted an arduous and busy process begins now for turning those documents into contracts, “hence enabling to rapidly bring forward and market our projects.”
“What remains to be done now is to move on so as to build a stronger relation based on mutual benefit, because we consider Russia a priority market for our products (CIGB) and this is a new step forward,” he commented.
In the meantime, the vice president of the Skolkovo Foundation, Alexander Chernov, said the signing of the documents corroborate the high level of cooperation reached by the two sides.
The signed agreements are pragmatic, it means cooperation, hard and productive work, he noted after saying that they will allow for pharmaceutical cooperation in different areas including those related to patents and licenses and the exchange of specialists.
According to Chernov, these agreements pave the way for the Russian party to access Latin American markets through Cuba, while allowing Cuban products to enter the European market through Russia.
Sponsored by the Russian state, the Skolkovo Foundation’s objective is to promote and market innovations in five key areas such as information technology, energy, space technology and telecommunications, nuclear technologies and biomedicine.
Worth mentioning is the SkolkovoInnovationCenter near Moscow, which aims to create an ideal situation in Russia to modernize the industry and promote innovation with development goals.
Meanwhile, the CIGB –founded on July 1, 1986 by the historic leader of the Cuban Revolution, Fidel Castro- is Cuba’s leading biotechnological center.
This scientific institution currently has more than 50 research and development projects that include human and animal vaccines, recombinant proteins for therapeutic use, synthetic peptides, monoclonal antibodies and diagnostic systems, among other products.Share on FB Share on TT